160 related articles for article (PubMed ID: 38110532)
61. Sputum cell-free DNA: Valued surrogate sample for the detection of EGFR exon 20 p.T790M mutation in patients with advanced lung adenocarcinoma and acquired resistance to EGFR-TKIs.
Wang Z; Li X; Zhang L; Xu Y; Wang M; Liang L; Jiao P; Li Y; He S; Du J; He L; Tang M; Sun M; Yang L; Di J; Zhu G; Li L; Liu D
Cancer Med; 2021 May; 10(10):3323-3331. PubMed ID: 33932095
[TBL] [Abstract][Full Text] [Related]
62. The Dynamic Use of
Macías M; Alegre E; Alkorta-Aranburu G; Patiño-García A; Mateos B; Andueza MP; Gúrpide A; Lopez-Picazo JM; Gil-Bazo I; Perez-Gracia JL; González Á
Dis Markers; 2019; 2019():7954921. PubMed ID: 30809319
[TBL] [Abstract][Full Text] [Related]
63. Liquid biopsy prediction of axillary lymph node metastasis, cancer recurrence, and patient survival in breast cancer: A meta-analysis.
Lee JH; Jeong H; Choi JW; Oh HE; Kim YS
Medicine (Baltimore); 2018 Oct; 97(42):e12862. PubMed ID: 30334995
[TBL] [Abstract][Full Text] [Related]
64. Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma.
Jiang T; Jiang L; Dong X; Gu K; Pan Y; Shi Q; Zhang G; Wang H; Zhang X; Yang N; Li Y; Xiong J; Yi T; Peng M; Song Y; Fan Y; Cui J; Chen G; Tan W; Zang A; Guo Q; Zhao G; Wang Z; He J; Yao W; Wu X; Chen K; Hu X; Hu C; Yue L; Jiang D; Wang G; Liu J; Yu G; Li J; Zhang H; Wu L; Fang L; Liang D; Zhao Y; Zhao W; Xie W; Ren S; Zhou C
Theranostics; 2021; 11(1):257-267. PubMed ID: 33391473
[No Abstract] [Full Text] [Related]
65. EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience.
Ianza A; Di Chicco A; Biagi C; Giudici F; Dicorato A; Guglielmi A; Variola F; Tomasi S; Roviello G; Generali D; Zanconati F
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2301-2307. PubMed ID: 34003366
[TBL] [Abstract][Full Text] [Related]
66. Characterization of the release and biological significance of cell-free DNA from breast cancer cell lines.
Wang W; Kong P; Ma G; Li L; Zhu J; Xia T; Xie H; Zhou W; Wang S
Oncotarget; 2017 Jun; 8(26):43180-43191. PubMed ID: 28574818
[TBL] [Abstract][Full Text] [Related]
67. Plasma cfDNA methylation markers for the detection and prognosis of ovarian cancer.
Liang L; Zhang Y; Li C; Liao Y; Wang G; Xu J; Li Y; Yuan G; Sun Y; Zhang R; Li X; Nian W; Zhao J; Zhang Y; Zhu X; Wen X; Cai S; Li N; Wu L
EBioMedicine; 2022 Sep; 83():104222. PubMed ID: 35973389
[TBL] [Abstract][Full Text] [Related]
68. Expanding the Full Potential of Liquid Biopsies for Lung Cancer Patients.
Rolfo C; Malapelle U; Russo A
Cancer Res; 2022 Aug; 82(16):2826-2828. PubMed ID: 35971678
[TBL] [Abstract][Full Text] [Related]
69. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease.
Moss J; Magenheim J; Neiman D; Zemmour H; Loyfer N; Korach A; Samet Y; Maoz M; Druid H; Arner P; Fu KY; Kiss E; Spalding KL; Landesberg G; Zick A; Grinshpun A; Shapiro AMJ; Grompe M; Wittenberg AD; Glaser B; Shemer R; Kaplan T; Dor Y
Nat Commun; 2018 Nov; 9(1):5068. PubMed ID: 30498206
[TBL] [Abstract][Full Text] [Related]
70. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
[TBL] [Abstract][Full Text] [Related]
71. Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC).
Gong Y; Nagarathinam R; Arisi MF; Gerratana L; Winn JS; Slifker M; Pei J; Cai KQ; Hasse Z; Obeid E; Noriega J; Sebastiano C; Ross E; Alpaugh K; Cristofanilli M; Fernandez SV
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445631
[TBL] [Abstract][Full Text] [Related]
72. Universal lung epithelium DNA methylation markers for detection of lung damage in liquid biopsies.
Magenheim J; Rokach A; Peretz A; Loyfer N; Cann G; Amini H; Moradi P; Nagaraju S; Sameer W; Cohen A; Fogel O; Kuint R; Abutbul A; Abu Rmeileh A; Karameh M; Cohen Goichman P; Wald O; Korach A; Neiman D; Fox-Fisher I; Moss J; Cohen D; Piyanzin S; Ben Ami R; Quteineh A; Golomb E; Shemer R; Glaser B; Kaplan T; Fridlender ZG; Dor Y
Eur Respir J; 2022 Nov; 60(5):. PubMed ID: 35450968
[TBL] [Abstract][Full Text] [Related]
73. Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma.
Park C; Na KJ; Choi H; Ock CY; Ha S; Kim M; Park S; Keam B; Kim TM; Paeng JC; Park IK; Kang CH; Kim DW; Cheon GJ; Kang KW; Kim YT; Heo DS
Theranostics; 2020; 10(23):10838-10848. PubMed ID: 32929383
[No Abstract] [Full Text] [Related]
74. Overexpression of Stat3 increases circulating cfDNA in breast cancer.
Wang YF; Wang XJ; Lu Z; Liu SR; Jiang Y; Wan XQ; Cheng CC; Shi LH; Wang LH; Ding Y
Breast Cancer Res Treat; 2021 May; 187(1):69-80. PubMed ID: 33630196
[TBL] [Abstract][Full Text] [Related]
75. Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer.
Palmero R; Taus A; Viteri S; Majem M; Carcereny E; Garde-Noguera J; Felip E; Nadal E; Malfettone A; Sampayo M; Riva F; Nagy RJ; Lanman RB; Faull I; Dix D; Karachaliou N; Rosell R
JCO Precis Oncol; 2021 Nov; 5():93-102. PubMed ID: 34994593
[TBL] [Abstract][Full Text] [Related]
76. Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients.
Koeppel F; Blanchard S; Jovelet C; Genin B; Marcaillou C; Martin E; Rouleau E; Solary E; Soria JC; André F; Lacroix L
PLoS One; 2017; 12(11):e0188174. PubMed ID: 29161279
[TBL] [Abstract][Full Text] [Related]
77. Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor.
Ku BM; Kim YJ; Park D; Lee SH; Ahn JS; Park K; Ahn MJ; Sun JM
Oncology; 2022; 100(4):228-237. PubMed ID: 35196661
[TBL] [Abstract][Full Text] [Related]
78. Genome-wide cell-free DNA methylation analyses improve accuracy of non-invasive diagnostic imaging for early-stage breast cancer.
Liu J; Zhao H; Huang Y; Xu S; Zhou Y; Zhang W; Li J; Ming Y; Wang X; Zhao S; Li K; Dong X; Ma Y; Qian T; Chen X; Xing Z; Zhang Y; Chen H; Liu Z; Pang D; Zhou M; Wu Z; Wang X; Wang X; Wu N; Su J
Mol Cancer; 2021 Feb; 20(1):36. PubMed ID: 33608029
[TBL] [Abstract][Full Text] [Related]
79. Identification of the plasma total cfDNA level before and after chemotherapy as an indicator of the neoadjuvant chemotherapy response in locally advanced breast cancer.
Ma G; Wang J; Huang H; Han X; Xu J; Veeramootoo JS; Xia T; Wang S
Cancer Med; 2020 Apr; 9(7):2271-2282. PubMed ID: 32017472
[TBL] [Abstract][Full Text] [Related]
80. Surveillance of cfDNA Hot Spot Mutations in NSCLC Patients during Disease Progression.
Sestokaite A; Gedvilaite V; Cicenas S; Sabaliauskaite R; Jarmalaite S
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
